These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33332891)

  • 1. Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: a real world, open-label experience.
    Velasco R; Besora S; Argyriou AA; Santos C; Sala R; Izquierdo C; Simó M; Gil-Gil M; Pardo B; Jiménez L; Clapés V; Calvo M; Palmero R; Bruna J
    Anticancer Drugs; 2021 Jan; 32(1):88-94. PubMed ID: 33332891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy.
    Battaglini E; Park SB; Barnes EH; Goldstein D
    Contemp Clin Trials; 2018 Jul; 70():135-138. PubMed ID: 29680317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial.
    Hirayama Y; Ishitani K; Sato Y; Iyama S; Takada K; Murase K; Kuroda H; Nagamachi Y; Konuma Y; Fujimi A; Sagawa T; Ono K; Horiguchi H; Terui T; Koike K; Kusakabe T; Sato T; Takimoto R; Kobune M; Kato J
    Int J Clin Oncol; 2015 Oct; 20(5):866-71. PubMed ID: 25762165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test.
    McCrary JM; Goldstein D; Wyld D; Henderson R; Lewis CR; Park SB
    J Cancer Surviv; 2019 Aug; 13(4):495-502. PubMed ID: 31172429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of the usefulness of duloxetine for chemotherapy-induced peripheral neuropathy.
    Kanbayashi Y; Inagaki M; Ueno H; Hosokawa T
    Med Oncol; 2017 Aug; 34(8):137. PubMed ID: 28687964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine Stress Axis-Dependence of Duloxetine Analgesia (Anti-Hyperalgesia) in Chemotherapy-Induced Peripheral Neuropathy.
    Staurengo-Ferrari L; Bonet IJM; Araldi D; Green PG; Levine JD
    J Neurosci; 2022 Jan; 42(3):405-415. PubMed ID: 34880120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601.
    Smith EM; Pang H; Ye C; Cirrincione C; Fleishman S; Paskett ED; Ahles T; Bressler LR; Le-Lindqwister N; Fadul CE; Loprinzi C; Shapiro CL;
    Eur J Cancer Care (Engl); 2017 Mar; 26(2):. PubMed ID: 26603828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysis.
    Chow R; Novosel M; So OW; Bellampalli S; Xiang J; Boldt G; Winquist E; Lock M; Lustberg M; Prsic E
    BMJ Support Palliat Care; 2023 Mar; 13(1):27-34. PubMed ID: 36194493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study.
    Ajewole VB; Cox JE; Swan JT; Chikermane SG; Lamoth B; Iso T; Okolo LO; Ford CL; Schneider AM; Hobaugh EC; Baker KR
    Support Care Cancer; 2020 Apr; 28(4):1901-1912. PubMed ID: 31359183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data.
    Gewandter JS; Kleckner AS; Marshall JH; Brown JS; Curtis LH; Bautista J; Dworkin RH; Kleckner IR; Kolb N; Mohile SG; Mustian KM
    Support Care Cancer; 2020 Jun; 28(6):2553-2562. PubMed ID: 31494735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.
    Smith EM; Pang H; Cirrincione C; Fleishman S; Paskett ED; Ahles T; Bressler LR; Fadul CE; Knox C; Le-Lindqwister N; Gilman PB; Shapiro CL;
    JAMA; 2013 Apr; 309(13):1359-67. PubMed ID: 23549581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
    Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
    Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial.
    Lu W; Giobbie-Hurder A; Freedman RA; Shin IH; Lin NU; Partridge AH; Rosenthal DS; Ligibel JA
    Oncologist; 2020 Apr; 25(4):310-318. PubMed ID: 32297442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-Induced Peripheral Neuropathy (CIPN) as a Predictor of Decreased Quality of Life in Testicular Germ Cell Tumor Survivors.
    Orszaghova Z; Galikova D; Lesko P; Obertova J; Rejlekova K; Sycova-Mila Z; Palacka P; Kalavska K; Svetlovska D; Mladosievicova B; Mardiak J; Mego M; Chovanec M
    Clin Genitourin Cancer; 2024 Jun; 22(3):102067. PubMed ID: 38555680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes.
    Battaglini E; Goldstein D; Grimison P; McCullough S; Mendoza-Jones P; Park SB
    J Natl Compr Canc Netw; 2021 Jul; 19(7):821-828. PubMed ID: 34340206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Structural Equation Approach With the Theory of Unpleasant Symptoms.
    Kim M; Jung MS
    Cancer Nurs; 2021 Mar-Apr 01; 44(2):145-153. PubMed ID: 31833921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention, diagnosis and management of chemotherapy-induced peripheral neuropathy: a cross-sectional study of French oncologists' professional practices.
    Selvy M; Pereira B; Kerckhove N; Busserolles J; Farsi F; Guastella V; Merle P; Pezet D; Balayssac D
    Support Care Cancer; 2021 Jul; 29(7):4033-4043. PubMed ID: 33403401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upper-limb dysfunction in cancer survivors with chemotherapy-induced peripheral neurotoxicity.
    Mahfouz FM; Li T; Joda M; Harrison M; Kumar S; Horvath LG; Grimison P; King T; Goldstein D; Park SB
    J Neurol Sci; 2024 Feb; 457():122862. PubMed ID: 38185015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-related differences in patient-reported and objective measures of chemotherapy-induced peripheral neuropathy among cancer survivors.
    Wong ML; Cooper BA; Paul SM; Abrams G; Topp K; Kober KM; Chesney MA; Mazor M; Schumacher MA; Conley YP; Levine JD; Miaskowski C
    Support Care Cancer; 2019 Oct; 27(10):3905-3912. PubMed ID: 30770977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors.
    Gewandter JS; Mohile SG; Heckler CE; Ryan JL; Kirshner JJ; Flynn PJ; Hopkins JO; Morrow GR
    Support Care Cancer; 2014 Jul; 22(7):1807-14. PubMed ID: 24531792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.